Drug Trial Radar · NCT04227600
A Study of JR-171 in Patients With Mucopolysaccharidosis I
Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Sep 1, 2020
Primary completion
Aug 2, 2022
Study completion Aug 2, 2022
Sponsor
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase I/II, open-label, multicenter, multinational (Japan, Brazil and US),designed to evaluate the safety, pharmacokinetics and explore the efficacy for the treatment of mucopolysaccharidosis type I (MPS I).
Conditions
- Mucopolysaccharidosis I
Interventions
JR-171 (lepunafusp alfa)Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: Time of the first dose of JR-171 until the last visit (Week 5 for Part 1/ Week 13 for Part 2).
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
Instituto de Genética e Erros Inatos do Metabolismo - IGEIM
São Paulo, Brazil
Fukuoka Children's Hospital
Fukuoka, Japan
Kochi Medical School Hospital
Nankoku, Japan
Osaka Metropolitan University Hospital
Osaka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.